Literature DB >> 21443535

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

G Fattovich1, L Covolo, S Bibert, G Askarieh, M Lagging, S Clément, G Malerba, M Pasino, M Guido, M Puoti, G B Gaeta, T Santantonio, G Raimondo, R Bruno, P-Y Bochud, F Donato, F Negro.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma and the identification of the predictors of response to antiviral therapy is an important clinical issue. AIM: To determine the independent contribution of factors including IL28B polymorphisms, IFN-gamma inducible protein-10 (IP-10) levels and the homeostasis model assessment of insulin resistance (HOMA-IR) score in predicting response to therapy in chronic hepatitis C (CHC).
METHODS: Multivariate analysis of factors predicting rapid (RVR) and sustained (SVR) virological response in 280 consecutive, treatment-naive CHC patients treated with peginterferon alpha and ribavirin in a prospective multicentre study.
RESULTS: Independent predictors of RVR were HCV RNA <400 000 IU/mL (OR 11.37; 95% CI 3.03-42.6), rs12980275 AA (OR 7.09; 1.97-25.56) and IP-10 (OR 0.04; 0.003-0.56) in HCV genotype 1 patients and lower baseline γ-glutamyl-transferase levels (OR=0.02; 0.0009-0.31) in HCV genotype 3 patients. Independent predictors of SVR were rs12980275 AA (OR 9.68; 3.44-27.18), age <40 years (OR=4.79; 1.50-15.34) and HCV RNA <400 000 IU/mL (OR 2.74; 1.03-7.27) in HCV genotype 1 patients and rs12980275 AA (OR=6.26; 1.98-19.74) and age <40 years (OR 5.37; 1.54-18.75) in the 88 HCV genotype 1 patients without a RVR. RVR was by itself predictive of SVR in HCV genotype 1 patients (OR 33.0; 4.06-268.32) and the only independent predictor of SVR in HCV genotype 2 (OR 9.0, 1.72-46.99) or genotype 3 patients (OR 7.8, 1.43-42.67).
CONCLUSIONS: In HCV genotype 1 patients, IL28B polymorphisms, HCV RNA load and IP-10 independently predict RVR. The combination of IL28B polymorphisms, HCV RNA level and age may yield more accurate pre-treatment prediction of SVR. HOMA-IR score is not associated with viral response.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21443535     DOI: 10.1111/j.1365-2036.2011.04635.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  30 in total

Review 1.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

Review 2.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

3.  The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents.

Authors:  Anu Osinusi; Susanna Naggie
Journal:  Eur Gastroenterol Hepatol Rev       Date:  2012

4.  CXC chemokine IP-10: a key actor in liver disease?

Authors:  Lin-Jiao Chen; Juan Lv; Xiao-Yu Wen; Jun-Qi Niu
Journal:  Hepatol Int       Date:  2013-07-16       Impact factor: 6.047

Review 5.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

Review 6.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 7.  Current and future therapies for hepatitis C virus infection.

Authors:  T Jake Liang; Marc G Ghany
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

8.  IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.

Authors:  C Carlton-Smith; J A Holmes; S Naggie; A Lidofsky; G M Lauer; A Y Kim; R T Chung
Journal:  J Viral Hepat       Date:  2017-12-27       Impact factor: 3.728

9.  IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.

Authors:  A S Rangnekar; R J Fontana
Journal:  J Viral Hepat       Date:  2013-01-07       Impact factor: 3.728

10.  High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.

Authors:  Susanne Johansson; Willem Talloen; Marianne Tuefferd; Jama Darling; Gregory Fanning; Michael W Fried; Jeroen Aerssens
Journal:  Liver Int       Date:  2015-09-06       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.